Yiyan Pei

Chengdu, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Baseline Nutritional Indices as Prognostic Indicators in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma Treated with the PD-L1 Inhibitor KL-A167: A Secondary Analysis of the KL-A167 Trial.

Baseline Nutritional Indices as Prognostic Indicators in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma Treated with the PD-L1 Inhibitor KL-A167: A Secondary Analysis of the KL-A167 Trial.

Journal: Cancer management and research

Published: March 30, 2026

Fullerene for Reducing Acute Radiation Dermatitis in Patients Undergoing Radiotherapy for Head and Neck Cancer: A Phase II, Double-Blind, Randomized Controlled Trial.

Fullerene for Reducing Acute Radiation Dermatitis in Patients Undergoing Radiotherapy for Head and Neck Cancer: A Phase II, Double-Blind, Randomized Controlled Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 20, 2026

Effect of Lithium Mouthwash on Oral Mucositis and Taste Dysfunction in Head and Neck Radiotherapy: The Phase I/II Clinical Trial.

Effect of Lithium Mouthwash on Oral Mucositis and Taste Dysfunction in Head and Neck Radiotherapy: The Phase I/II Clinical Trial.

Journal: International journal of radiation oncology, biology, physics

Published: February 27, 2026

Antibiotic exposure and cancer risk: an umbrella review elucidating the direction of risk across 14 malignancies.

Antibiotic exposure and cancer risk: an umbrella review elucidating the direction of risk across 14 malignancies.

Journal: Journal of public health (Oxford, England)

Published: February 04, 2026

Multidisciplinary Team Support for Patients With Head and Neck Cancer Receiving Radiotherapy: A Randomized Clinical Trial.

Multidisciplinary Team Support for Patients With Head and Neck Cancer Receiving Radiotherapy: A Randomized Clinical Trial.

Journal: JAMA network open

Published: December 15, 2025

Correction: Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors.

Correction: Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors.

Journal: Cancer immunology, immunotherapy : CII

Published: September 29, 2025

Correction: Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167).

Correction: Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167).

Journal: Cancer immunology, immunotherapy : CII

Published: September 29, 2025

Prognostic Impact of Advanced Lung Cancer Inflammation Index (ALI) on Immunotherapy Outcomes in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter Post Hoc Analysis.

Prognostic Impact of Advanced Lung Cancer Inflammation Index (ALI) on Immunotherapy Outcomes in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter Post Hoc Analysis.

Journal: Journal of inflammation research

Published: June 15, 2025

Corrigendum: Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors.

Corrigendum: Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors.

Journal: Frontiers in oncology

Published: April 11, 2025

Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors.

Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors.

Journal: Frontiers in oncology

Published: December 04, 2024

Machine Learning-based Prognostic Model for Brain Metastasis Patients: Insights from Blood Test Analysis.

Machine Learning-based Prognostic Model for Brain Metastasis Patients: Insights from Blood Test Analysis.

Journal: Journal of Cancer

Published: September 18, 2024

Immune-related adverse events as prognostic biomarkers in recurrent or metastatic nasopharyngeal carcinoma receiving PD-L1 inhibitor: A post-hoc analysis of the multicenter, single-arm, phase 2 study.

Immune-related adverse events as prognostic biomarkers in recurrent or metastatic nasopharyngeal carcinoma receiving PD-L1 inhibitor: A post-hoc analysis of the multicenter, single-arm, phase 2 study.

Journal: Oral oncology

Published: September 09, 2024

Showing 1-12 of 32

Last Updated: 09/26/2026